Abstract
Glycogen phosphorylase (GP), a validated target for the development of anti-hyperglycaemic agents, has been targeted for the design of novel glycopyranosylamine inhibitors. Exploiting the two most potent inhibitors from our previous study of N-acyl-β-D-glucopyranosylamines (Parmenopoulou et al., Bioorg. Med. Chem. 2014, 22, 4810), we have extended the linking group to –NHCONHCO- between the glucose moiety and the aliphatic/aromatic substituent in the GP catalytic site β-cavity. The N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors were synthesized and their efficiency assessed by biochemical methods, revealing inhibition constant values of 4.95 µM and 2.53 µM. Crystal structures of GP in complex with these inhibitors were determined and analyzed, providing data for further structure based design efforts. A novel Linear Response – Molecular Mechanics Coulomb Surface Area (LR-MM-CBSA) method has been developed which relates predicted and experimental binding free energies for a training set of N-acyl-N´-(β-D-glucopyranosyl) urea ligands with a correlation coefficient R2 of 0.89 and leave-one-out cross-validation (LOO-cv) Q2 statistic of 0.79. The method has significant applications to direct future lead optimization studies, where ligand entropy loss on binding is revealed as a key factor to be considered. ADMET property predictions revealed that apart from potential permeability issues, the synthesized N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors have drug-like potential without any toxicity warnings.
Keywords: Glycogen phosphorylase, X-ray crystallography, Diabetes type 2, N-acyl-β-D-glucopyranosyl ureas, Binding free energy, Linear response methods.
Current Topics in Medicinal Chemistry
Title:Glycogen Phosphorylase as a Target for Type 2 Diabetes: Synthetic, Biochemical, Structural and Computational Evaluation of Novel N-acyl-N´-(β-D-glucopyranosyl) Urea Inhibitors
Volume: 15 Issue: 23
Author(s): Anastassia L. Kantsadi, Vanessa Parmenopoulou, Dimitar N. Bakalov, Laura Snelgrove, George A. Stravodimos, Demetra S.M. Chatzileontiadou, Stella Manta, Angeliki Panagiotopoulou, Joseph M. Hayes, Dimitri Komiotis and Demetres D. Leonidas
Affiliation:
Keywords: Glycogen phosphorylase, X-ray crystallography, Diabetes type 2, N-acyl-β-D-glucopyranosyl ureas, Binding free energy, Linear response methods.
Abstract: Glycogen phosphorylase (GP), a validated target for the development of anti-hyperglycaemic agents, has been targeted for the design of novel glycopyranosylamine inhibitors. Exploiting the two most potent inhibitors from our previous study of N-acyl-β-D-glucopyranosylamines (Parmenopoulou et al., Bioorg. Med. Chem. 2014, 22, 4810), we have extended the linking group to –NHCONHCO- between the glucose moiety and the aliphatic/aromatic substituent in the GP catalytic site β-cavity. The N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors were synthesized and their efficiency assessed by biochemical methods, revealing inhibition constant values of 4.95 µM and 2.53 µM. Crystal structures of GP in complex with these inhibitors were determined and analyzed, providing data for further structure based design efforts. A novel Linear Response – Molecular Mechanics Coulomb Surface Area (LR-MM-CBSA) method has been developed which relates predicted and experimental binding free energies for a training set of N-acyl-N´-(β-D-glucopyranosyl) urea ligands with a correlation coefficient R2 of 0.89 and leave-one-out cross-validation (LOO-cv) Q2 statistic of 0.79. The method has significant applications to direct future lead optimization studies, where ligand entropy loss on binding is revealed as a key factor to be considered. ADMET property predictions revealed that apart from potential permeability issues, the synthesized N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors have drug-like potential without any toxicity warnings.
Export Options
About this article
Cite this article as:
L. Kantsadi Anastassia, Parmenopoulou Vanessa, N. Bakalov Dimitar, Snelgrove Laura, A. Stravodimos George, S.M. Chatzileontiadou Demetra, Manta Stella, Panagiotopoulou Angeliki, M. Hayes Joseph, Komiotis Dimitri and D. Leonidas Demetres, Glycogen Phosphorylase as a Target for Type 2 Diabetes: Synthetic, Biochemical, Structural and Computational Evaluation of Novel N-acyl-N´-(β-D-glucopyranosyl) Urea Inhibitors, Current Topics in Medicinal Chemistry 2015; 15 (23) . https://dx.doi.org/10.2174/1568026615666150619142253
DOI https://dx.doi.org/10.2174/1568026615666150619142253 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
Current Pharmaceutical Design Structure and Enzymatic Activities of Human Serum Albumin
Current Pharmaceutical Design Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Non-Invasive Methods of Glucose Measurement: Current Status and Future Perspectives
Current Diabetes Reviews Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement
Current Vascular Pharmacology Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Leukostasis for the Treatment of Early Diabetic Retinopathy
Cardiovascular & Hematological Disorders-Drug Targets Perspectives in Therapeutic Innovation in Ocular Surface Disorders and Dry Eye Syndrome
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Thiazide Diuretics: 50 Years and Beyond
Current Hypertension Reviews Wnt Signaling in Development, Disease and Translational Medicine
Current Drug Targets Mitochondrial Disorders in Adults
Current Molecular Medicine Fruit Wines Inhibitory Activity Against α-Glucosidase
Current Pharmaceutical Biotechnology Multicomponent Reactions for the Synthesis of Bioactive Compounds: A Review
Current Organic Synthesis Oxidation Inhibits Iron-Induced Blood Coagulation
Current Drug Targets Impact of Diabetes on Vasculature: Focus on Nervous System
Current Diabetes Reviews